Tvardi Therapeutics Funding: $74M Raised, Series B (2021)
Tvardi Therapeutics is based in Houston. It has raised $74M in total funding. Latest round: Series B.
Tvardi Therapeutics funding overview
Tvardi Therapeutics is based in Houston. Tvardi Therapeutics has raised $74M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in June 2021. The round record for Tvardi Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Slate Path Capital, Palkon Capital, ArrowMark Partners, 683 Capital, Sporos Bioventures. 5 distinct backers are named across the disclosed rounds.
Frequently asked about Tvardi Therapeutics funding
How much has Tvardi Therapeutics raised?
Tvardi Therapeutics has raised $74M in total disclosed funding across the rounds on record.
Who has invested in Tvardi Therapeutics?
Slate Path Capital, Palkon Capital, ArrowMark Partners, 683 Capital, Sporos Bioventures are named among the investors backing Tvardi Therapeutics.
What was the latest Tvardi Therapeutics funding round?
The most recent disclosed round is a Series B, announced in June 2021.
Where is Tvardi Therapeutics based?
Tvardi Therapeutics is based in Houston.
When did Tvardi Therapeutics last raise?
The last disclosed Tvardi Therapeutics round closed in June 2021 at Series B.
We update the Tvardi Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Houston and their backers are listed below.
